Thank you Dr. Dowd, for your interest and comments - and I broadly agree, we need to understand more about non-pharmacological appraoches and their impact on disease. Obviously collectively this has progressed well in PsA and to a lesser extent in RA and OA.
What I think semaglutide has changed is how actionable this all is across a broader population - and I suspect myself and others haven't had as much success with dietary approaches in practice than you have. This is easier for patients, and even if we are suggesting it actively, patients will have thought about it before we have. It's clearly incumbent upon us to make sure we are advocating for 'lifestyle measures', before, during, and potentially after GLP-1 agonists.
What I think it also might actually do, further to your points, is revitalize thinking about obesity and RA/PsA/OA and actually further research in these areas, including along the lines of what you suggest.
Either way, it's changing rheumatology, whether we like it or not! Thanks once again for your comment and for following our coverage.
Thank you Dr. Dowd, for your interest and comments - and I broadly agree, we need to understand more about non-pharmacological appraoches and their impact on disease. Obviously collectively this has progressed well in PsA and to a lesser extent in RA and OA.
What I think semaglutide has changed is how actionable this all is across a broader population - and I suspect myself and others haven't had as much success with dietary approaches in practice than you have. This is easier for patients, and even if we are suggesting it actively, patients will have thought about it before we have. It's clearly incumbent upon us to make sure we are advocating for 'lifestyle measures', before, during, and potentially after GLP-1 agonists.
What I think it also might actually do, further to your points, is revitalize thinking about obesity and RA/PsA/OA and actually further research in these areas, including along the lines of what you suggest.
Either way, it's changing rheumatology, whether we like it or not! Thanks once again for your comment and for following our coverage.